[[ type === 'moc' ? 'MARKET ON CLOSE' : 'FREE WEBINAR' ]]
[[ timeLabel ]] WATCH LIVE:
Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Join Barchart Premier to attend LIVE "Market on Close" program each Friday with John Rowland. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Pacira Pharm Inc (PCRX)

Pacira Pharm Inc (PCRX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]] ([[ financialData.relativeStrengthDirection14d ]]) ([[ financialData.highPercent1y ]]) ([[ financialData.lowPercent1y ]])
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 910,906
  • Shares Outstanding, K 39,348
  • Annual Sales, $ 726,410 K
  • Annual Income, $ 7,030 K
  • EBIT $ 81 M
  • EBITDA $ 170 M
  • 60-Month Beta 0.32
  • Price/Sales 1.28
  • Price/Cash Flow 6.13
  • Price/Book 1.42

Options Overview Details

View History
  • Implied Volatility 44.88% (+3.92%)
  • Historical Volatility 34.20%
  • IV Percentile 3%
  • IV Rank 6.50%
  • IV High 128.93% on 03/16/26
  • IV Low 39.03% on 08/20/25
  • Expected Move (DTE 3) 0.00 (0.00%)
  • Put/Call Vol Ratio 0.04
  • Today's Volume 24
  • Volume Avg (30-Day) 43
  • Put/Call OI Ratio 0.24
  • Today's Open Interest 1,659
  • Open Int (30-Day) 1,258
  • Expected Range 22.74 to 22.74

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Buy
Based on 8 analysts offering recommendations.
Earnings Estimates - Current Qtr 06/30/26
See More
  • Average Estimate $0.27
  • Number of Estimates 1
  • High Estimate $0.27
  • Low Estimate $0.27
  • Prior Year $0.47
  • Growth Rate Est. (year over year) -42.55%

Price Performance

See More
Period Period Low Period High Performance
1-Month
22.46 +1.25%
on 05/11/26
27.13 -16.18%
on 05/01/26
-1.05 (-4.41%)
since 04/10/26
3-Month
20.62 +10.28%
on 02/27/26
27.13 -16.18%
on 05/01/26
+1.01 (+4.65%)
since 02/11/26
52-Week
18.80 +20.96%
on 01/20/26
27.64 -17.73%
on 09/03/25
-2.38 (-9.47%)
since 05/09/25

Most Recent Stories

More News
Pacira BioSciences Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

BRISBANE, Calif., May 08, 2026 (GLOBE NEWSWIRE) -- Pacira BioSciences, Inc. (Nasdaq: PCRX), the industry leader in the delivery of innovative, non-opioid pain therapies to transform the lives of patients,...

PCRX : 22.74 (-1.77%)
Pacira BioSciences Mails Letter to Stockholders

Details Success of Pacira’s 5x30 Strategy and Solid First Quarter 2026 Results  Reiterates Board’s Unanimous Recommendation that Stockholders Vote “FOR” the Election of Pacira’s Highly...

PCRX : 22.74 (-1.77%)
Pacira: Q1 Earnings Snapshot

Pacira: Q1 Earnings Snapshot

PCRX : 22.74 (-1.77%)
Pacira BioSciences Reports First Quarter 2026 Financial Results

-- Total revenue of $177 million, reflecting increase of 5 percent over first quarter 2025 driven by growth across commercial portfolio, including EXPAREL volume growth of 7 percent -- -- Completed...

PCRX : 22.74 (-1.77%)
Pacira's Non-Opioid Thesis Meets Its Most Important Quarter Since the Proxy Fight Began

Barchart Research What to Expect from PCRX Earnings PCRX Generated April 29, 2026 Current Price $25.14 EPS Estimate $$0.33 Consensus Rating Moderate Buy Average Move 3.99% Pacira's Non-Opioid Thesis Meets...

PCRX : 22.74 (-1.77%)
Pacira BioSciences Files Definitive Proxy Materials and Mails Letter to Shareholders

Urges Stockholders to Vote “FOR” Pacira’s Highly Qualified Nominees on the  BLUE Proxy Card Today Strongly Opposes the Election of Each of DOMA’s Underqualified Nominees BRISBANE,...

PCRX : 22.74 (-1.77%)
Real-World Data on EXPAREL® Shows Reduced Opioid Use and Lower Total Medical Costs in Medicare Patients Undergoing Total Hip Arthroplasty

BRISBANE, Calif., April 27, 2026 (GLOBE NEWSWIRE) -- Pacira BioSciences, Inc. (NASDAQ: PCRX), the industry leader in its commitment to deliver innovative, non-opioid pain therapies to transform the lives...

PCRX : 22.74 (-1.77%)
Pacira to Report First Quarter 2026 Financial Results on Thursday April 30, 2026

BRISBANE, Calif., April 16, 2026 (GLOBE NEWSWIRE) -- Pacira BioSciences, Inc. (Nasdaq: PCRX), the industry leader in its commitment to deliver innovative, non-opioid pain therapies to transform the lives...

PCRX : 22.74 (-1.77%)
Pacira Presents Real-World Data on EXPAREL® Showing Lower Total Healthcare Costs in Outpatient Total Hip and Knee Arthroplasty Procedures

-- Select findings demonstrate that the use of EXPAREL ® (bupivacaine liposome injectable suspension) in outpatient Total Hip Arthroplasty (THA) and Total Knee Arthroplasty (TKA) is associated...

PCRX : 22.74 (-1.77%)
Pacira BioSciences to Participate in Fireside Chat at the 25th Annual Needham Virtual Healthcare Conference

BRISBANE, Calif., April 08, 2026 (GLOBE NEWSWIRE) -- Pacira BioSciences, Inc. (Nasdaq: PCRX), the industry leader in its commitment to deliver innovative, non-opioid pain therapies to transform the lives...

PCRX : 22.74 (-1.77%)

Business Summary

Pacira BioSciences, Inc. is a specialty pharmaceutical company focused on the development, commercialization and manufacture of proprietary pharmaceutical products primarily for use in hospitals and ambulatory surgery centers. These products are developed using the company's proprietary DepoFoam drug...

See More

Key Turning Points

3rd Resistance Point 24.68
2nd Resistance Point 24.18
1st Resistance Point 23.46
Last Price 22.74
1st Support Level 22.24
2nd Support Level 21.74
3rd Support Level 21.02

See More

52-Week High 27.64
Fibonacci 61.8% 24.26
Fibonacci 50% 23.22
Last Price 22.74
Fibonacci 38.2% 22.18
52-Week Low 18.80

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.